PFOB sonosensitive microdroplets: determining their interaction radii with focused ultrasound using MR thermometry and a Gaussian convolution kernel computation

References

• Lyon PC, Griffiths LF, Lee J, et al. Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours. J Ther Ultrasound. 2017;5(1):28.
   PubMedGoogle Scholar
• Lyon PC. Targeted release from lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours [doctoral dissertation]. Oxford, UK: University of Oxford; 2016.
   Google Scholar
• Al Rifai N, Desgranges S, Le Guillou-Buffello D, et al. Ultrasound-triggered delivery of paclitaxel encapsulated in an emulsion at low acoustic pressures. J Mater Chem B. 2020;8(8):1640–1648.
   PubMed Web of Science ®Google Scholar
• Harper JD, Metzler I, Hall MK, et al. First in-Human burst wave lithotripsy for kidney stone comminution: Initial two case studies. J Endourol. 2021;35(4):506–511.
   PubMed Web of Science ®Google Scholar
• Petit B. Microbubble-mediated sonothrombolysis: an in vitro mechanistic study [doctoral dissertation]. Geneva, Switzerland: University of Geneva; 2014.
   Google Scholar
• Napoli A, Anzidei M, De Nunzio C, et al. Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: preliminary experience. Eur Urol. 2013;63(2):395–398.
   PubMed Web of Science ®Google Scholar
• Okada A, Murakami T, Mikami K, et al. A case of hepatocellular carcinoma treated by MR-guided focused ultrasound ablation with respiratory gating. Magn Reson Med Sci. 2006;5(3):167–171.
   PubMedGoogle Scholar
• Mori N, Jud C, Salomir R, et al. Leveraging respiratory organ motion for non-invasive tumor treatment devices: a feasibility study. Phys Med Biol. 2016;61(11):4247–4267.
   PubMed Web of Science ®Google Scholar
• Salomir R, Petrusca L, Auboiroux V, et al. Magnetic resonance-guided shielding of prefocal acoustic obstacles in focused ultrasound therapy: application to intercostal ablation in liver. Invest Radiol. 2013;48(6):366–380.
   PubMed Web of Science ®Google Scholar
• Desgranges S, Lorton O, Gui-Levy L, et al. Micron-sized PFOB liquid core droplets stabilized with tailored-made perfluorinated surfactants as a new class of endovascular sono-sensitizers for focused ultrasound thermotherapy. J Mater Chem B. 2019;7(6):927–939.
   PubMed Web of Science ®Google Scholar
• Guillemin PC, Gui L, Lorton O, et al. Mild hyperthermia by MR-guided focused ultrasound in an ex vivo model of osteolytic bone tumour: optimization of the spatio-temporal control of the delivered temperature. J Transl Med. 2019;17(1):1–19.
   PubMed Web of Science ®Google Scholar
• Muller A, Petrusca L, Auboiroux V, et al. Management of respiratory motion in extracorporeal high-intensity focused ultrasound treatment in upper abdominal organs: current status and perspectives. Cardiovasc Intervent Radiol. 2013;36(6):1464–1476.
   PubMed Web of Science ®Google Scholar
• Lorton O, Guillemin PC, Möri N, et al. Self-scanned HIFU ablation of moving tissue using real-time hybrid US-MR imaging. IEEE Trans Biomed Eng. 2019;66(8):2182–2191.
   PubMed Web of Science ®Google Scholar
• Aubry J-F, Pauly KB, Moonen C, et al. The road to clinical use of high-intensity focused ultrasound for liver cancer: technical and clinical consensus. J Ther Ultrasound. 2013;1(13):13–13.
   PubMedGoogle Scholar
• Melodelima D, Salomir R, Mougenot C, et al. Intraluminal ultrasound applicator compatible with magnetic resonance imaging “ "real-time" temperature mapping for the treatment of oesophageal tumours: an ex vivo study”. Med Phys. 2004;31(2):236–244.
   PubMed Web of Science ®Google Scholar
• Diana M, Schiraldi L, Liu Y-Y, et al. High intensity focused ultrasound (HIFU) applied to hepato-bilio-pancreatic and the digestive system-current state of the art and future perspectives. Hepatobiliary Surg Nutr. 2016;5(4):329–344.
   PubMed Web of Science ®Google Scholar
• Frinking P, Segers T, Luan Y, et al. Three decades of ultrasound contrast agents: a review of the past, present and future improvements. Ultrasound Med Biol. 2020;46(4):892–908.
   PubMed Web of Science ®Google Scholar
• Piscaglia F, Nolsøe C, Dietrich CFa, et al. The EFSUMB guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med. 2012;33(1):33–59.
   PubMed Web of Science ®Google Scholar
• EMEA/H/C/000303 - Sonovue EPAR Product Information: European Medicines Agency; [June 2021]. Available from: https://www.ema.europa.eu/en/documents/product-information/sonovue-epar-product-information_en.pdf.
   Google Scholar
• Peng S, Xiong Y, Li K, et al. Clinical utility of a microbubble-enhancing contrast (“SonoVue”) in treatment of uterine fibroids with high intensity focused ultrasound: a retrospective study. Eur J Radiol. 2012;81(12):3832–3838.
   PubMed Web of Science ®Google Scholar
• Chen Y, Jiang J, Zeng Y, et al. Effects of a microbubble ultrasound contrast agent on high-intensity focused ultrasound for uterine fibroids: a randomised controlled trial. Int J Hyperthermia. 2018;34(8):1311–1315.
   PubMed Web of Science ®Google Scholar
• Isern J, Pessarrodona A, Rodriguez J, et al. Using microbubble sonographic contrast agent to enhance the effect of high intensity focused ultrasound for the treatment of uterine fibroids. Ultrason Sonochem. 2015;27:688–693.
   PubMed Web of Science ®Google Scholar
• Jiang N, Xie B, Zhang X, et al. Enhancing ablation effects of a microbubble-enhancing contrast agent (“SonoVue”) in the treatment of uterine fibroids with high-intensity focused ultrasound: a randomized controlled trial. Cardiovasc Intervent Radiol. 2014;37(5):1321–1328.
   PubMed Web of Science ®Google Scholar
• Jiang H, Luo S, Min HE, et al. A retrospective study: high intensity focused ultrasound (HIFU) associated a microbubble-enhancing contrast (“SonoVue”) therapy for uterine fibroids with pelvic operation history. Journal of Kunming Medical University. 2013;9:58–62.
   Google Scholar
• Jingqi W, Lu Z, Jun Z, et al. Clinical usefulness of the microbubble contrast agent sonovue in enhancing the effects of High-Intensity Focused Ultrasound for the Treatment of Adenomyosis. J Ultrasound Med. 2018;37(12):2811–2819.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhou K, Zhang J, et al. Efficacy and safety of high-intensity focused ultrasound ablation for hepatocellular carcinoma by changing the acoustic environment: microbubble contrast agent (SonoVue) and transcatheter arterial chemoembolization. Int J Hyperthermia. 2019;36(1):243–251.
   Web of Science ®Google Scholar
• Tung YS, Liu HL, Wu CC, et al. Contrast-agent-enhanced ultrasound thermal ablation. Ultrasound Med Biol. 2006;32(7):1103–1110.
   PubMed Web of Science ®Google Scholar
• Moyer LC, Timbie KF, Sheeran PS, et al. High-intensity focused ultrasound ablation enhancement in vivo via phase-shift nanodroplets compared to microbubbles. J Ther Ultrasound. 2015;3:7.
   PubMedGoogle Scholar
• Fabiilli ML, Piert MR, Koeppe RA, et al. Assessment of the biodistribution of an [(18) F]FDG-loaded perfluorocarbon double emulsion using dynamic micro-PET in rats. Contrast Media Mol Imaging. 2013;8(4):366–374.
   PubMed Web of Science ®Google Scholar
• Kripfgans OD, Zhang M, Fabiilli ML, et al. Acceleration of ultrasound thermal therapy by patterned acoustic droplet vaporization. J Acoust Soc Am. 2014;135(1):537–544.
   PubMed Web of Science ®Google Scholar
• Zhu M, Jiang L, Fabiilli ML, et al. Treatment of murine tumors using acoustic droplet vaporization-enhanced high intensity focused ultrasound. Phys Med Biol. 2013;58(17):6179–6191.
   PubMed Web of Science ®Google Scholar
• Kripfgans OD, Fowlkes JB, Woydt M, et al. In vivo droplet vaporization for occlusion therapy and phase aberration correction. IEEE Trans Ultrason, Ferroelect, Freq Contr. 2002;49(6):726–738.
   PubMed Web of Science ®Google Scholar
• Lo AH, Kripfgans OD, Carson PL, et al. Acoustic droplet vaporization threshold: effects of pulse duration and contrast agent. IEEE Trans Ultrason Ferroelectr Freq Control. 2007;54(5):933–946.
   PubMed Web of Science ®Google Scholar
• Rapoport N, Nam K-H, Gupta R, et al. Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions. J Control Release. 2011;153(1):4–15.
   PubMed Web of Science ®Google Scholar
• Zhang P, Porter T. An in vitro study of a phase-shift nanoemulsion: a potential nucleation agent for bubble-enhanced HIFU tumor ablation. Ultrasound Med Biol. 2010;36(11):1856–1866.
   PubMed Web of Science ®Google Scholar
• Kopechek JA, Park E, Mei CS, et al. Accumulation of phase-shift nanoemulsions to enhance MR-guided ultrasound-mediated tumor ablation in vivo. J Healthc Eng. 2013;4(1):109–126.
   PubMed Web of Science ®Google Scholar
• Guédra M, Valier-Brasier T, Conoir J-M, et al. Influence of shell compressibility on the ultrasonic properties of polydispersed suspensions of nanometric encapsulated droplets. J Acoust Soc Am. 2014;135(3):1044–1055.
   PubMed Web of Science ®Google Scholar
• Lacour T, Guédra M, Valier-Brasier T, et al. A model for acoustic vaporization dynamics of a bubble/droplet system encapsulated within a hyperelastic shell. J Acoust Soc Am. 2018;143(1):23–37.
   PubMed Web of Science ®Google Scholar
• Guédra M, Coulouvrat F. A model for acoustic vaporization of encapsulated droplets. J Acoust Soc Am. 2015;138(6):3656–3667.
   PubMed Web of Science ®Google Scholar
• Coulouvrat F, Thomas J-L, Astafyeva K, et al. A model for ultrasound absorption and dispersion in dilute suspensions of nanometric contrast agents. J Acoust Soc Am. 2012;132(6):3748–3759.
   PubMed Web of Science ®Google Scholar
• Pitt WG, Singh RN, Perez KX, et al. Phase transitions of perfluorocarbon nanoemulsion induced with ultrasound: a mathematical model. Ultrason Sonochem. 2014;21(2):879–891.
   PubMed Web of Science ®Google Scholar
• Doinikov AA, Sheeran PS, Bouakaz A, et al. Vaporization dynamics of volatile perfluorocarbon droplets: a theoretical model and in vitro validation. Med Phys. 2014;41(10):102901.
   PubMed Web of Science ®Google Scholar
• Lorton O, Guillemin PC, Holman R, et al. Enhancement of HIFU thermal therapy in perfused tissue models using micron-sized FTAC-stabilized PFOB-core endovascular sonosensitizers. Int J Hyperthermia. 2020;37(1):1116–1130.
   PubMed Web of Science ®Google Scholar
• EU/3/20/2383 - Perflubron for the treatment of respiratory distress syndrome: European Medicines Agency; [June 2021]. Available from: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/20/2383-public-summary-opinion-orphan-designation-perflubron-treatment-respiratory-distress-syndrome_en.pdf.
   Google Scholar
• EU/3/20/2361 - Perflubron for the treatment of congenital pulmonary hypoplasia: European Medicines Agency; [June 2021]. Available from: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/20/2361-public-summary-opinion-orphan-designation-perflubron-treatment-congenital-pulmonary-hypoplasia_en.pdf.
   Google Scholar
• Kripfgans OD, Fabiilli ML, Carson PL, et al. On the acoustic vaporization of micrometer-sized droplets. J Acoust Soc Am. 2004;116(1):272–281.
   PubMed Web of Science ®Google Scholar
• Zhang M, Fabiilli ML, Haworth KJ, et al. Acoustic droplet vaporization for enhancement of thermal ablation by high intensity focused ultrasound. Acad Radiol. 2011;18(9):1123–1132.
   PubMed Web of Science ®Google Scholar
• Lea-Banks H, O'Reilly M, Hynynen K. Ultrasound-responsive droplets for therapy: a review. J Control Release. 2019;293:144–154.
   PubMed Web of Science ®Google Scholar
• Lu Y, Gu Z. Kidney physiology: a size bandpass filter. Nat Nanotechnol. 2017;12(11):1023–1025.
   PubMed Web of Science ®Google Scholar
• Muzykantov V, Muro S. Targeting delivery of drugs in the vascular system. Int J Transp Phenom. 2011;12(1-2):41–49.
   PubMedGoogle Scholar
• Wisse E, Jacobs F, Topal B, et al. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 2008;15(17):1193–1199.
   PubMed Web of Science ®Google Scholar
• Ranieri G, Laforgia M, Nardulli P, et al. Oxaliplatin-Based intra-arterial chemotherapy in Colo-Rectal cancer liver metastases: a review from pharmacology to clinical application. Cancers. 2019;11(2):141–156.
   PubMed Web of Science ®Google Scholar
• Stehling MK, Turner R, Mansfield P. Echo-planar imaging: magnetic resonance imaging in a fraction of a second. Science. 1991;254(5028):43–50.
   PubMed Web of Science ®Google Scholar
• Jägers J, Wrobeln A, Ferenz KB. Perfluorocarbon-based oxygen carriers: from physics to physiology. Pflugers Arch. 2021;473(2):139–150.
   PubMed Web of Science ®Google Scholar
• Meltzer RS, Tickner EG, Popp RL. Why do the lungs clear ultrasonic contrast? Ultrasound Med Biol. 1980;6(3):263–269.
   PubMed Web of Science ®Google Scholar
• Mattrey RF, Andrè M, Campbell J, et al. Specific enhancement of intra-abdominal abscesses with perfluoroctylbromide for CT imaging. Invest Radiol. 1984;19(5):438–446.
   PubMed Web of Science ®Google Scholar
• Kim S, Chen J, Cheng T, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49(D1):D1388–D1395.
   PubMed Web of Science ®Google Scholar
• Long DC, Long DM, Riess J, et al. Preparation and application of highly concentrated perfluoroctylbromide fluorocarbon emulsions. Biomater Artif Cells Artif Organs. 1988;16(1-3):441–442.
   PubMed Web of Science ®Google Scholar
• Clark LC, Jr Wesseler EP, Miller ML, et al. Ring versus straight chain perfluorocarbon emulsions for perfusion media. Microvasc Res. 1974;8(3):320–340.
   PubMed Web of Science ®Google Scholar
• Mattrey RF. Perfluorooctylbromide: a new contrast agent for CT, sonography, and MR imaging. AJR Am J Roentgenol. 1989;152(2):247–252.
   PubMed Web of Science ®Google Scholar
• Burgan AR, Long DM, Mattrey RF. Results of pharmacokinetic and toxicologic studies with PFOB emulsions. Biomater Artif Cells Artif Organs. 1987;15(2):403.
   Google Scholar
• Spahn D. Blood substitutes artificial oxygen carriers: perfluorocarbon emulsions. Crit Care. 1999;3(5):R93–R97.
   PubMed Web of Science ®Google Scholar
• Long DM, Liu M-S, Szanto PS, et al. Efficacy and toxicity studies with radiopaque perfluorocarbon. Radiology. 1972;105(2):323–332.
   PubMed Web of Science ®Google Scholar
• Leese PT, Noveck RJ, Shorr JS, et al. Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers. Anesth Analg. 2000;91(4):804–811.
   PubMed Web of Science ®Google Scholar
• Noveck RJ, Shannon EJ, Leese PT, et al. Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. Anesth Analg. 2000;91(4):812–822.
   PubMed Web of Science ®Google Scholar
• Hill SE, Leone BJ, Faithfull NS, et al. Perflubron emulsion (AF0144) augments harvesting of autologous blood: a phase II study in cardiac surgery. J Cardiothorac Vasc Anesth. 2002;16(5):555–560.
   PubMed Web of Science ®Google Scholar
• Swystun V, Green FHY, Dennis JH, et al. A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma. Trials. 2018;19(1):321.
   PubMed Web of Science ®Google Scholar
• Green FHY, Leigh R, Fadayomi M, et al. A phase I, placebo-controlled, randomized, double-blind, single ascending dose-ranging study to evaluate the safety and tolerability of a novel biophysical bronchodilator (S-1226) administered by nebulization in healthy volunteers. Trials. 2016;17(1):361.
   PubMed Web of Science ®Google Scholar
• Leach CL, Greenspan JS, Rubenstein SD, et al. Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent study group. N Engl J Med. 1996;335(11):761–767.
   PubMed Web of Science ®Google Scholar
• Wolfson MR, Kechner NE, Roache RF, et al. Perfluorochemical rescue after surfactant treatment: effect of perflubron dose and ventilatory frequency. J Appl Physiol (1985). 1998;84(2):624–640.
   PubMed Web of Science ®Google Scholar
• Bruneton JN, Falewee MN, Balu-Maestro C, et al. Perfluoroctylbromide and hepatosplenic computed tomography. Preliminary clinical study. Invest Radiol. 1988;23:S306–S307.
   PubMed Web of Science ®Google Scholar
• Mattrey RF, Strich G, Shelton RE, et al. Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results. Radiology. 1987;163(2):339–343.
   PubMed Web of Science ®Google Scholar
• Mattrey RF, Hajek PC, Gylys-Morin VM, et al. Perfluorochemicals as gastrointestinal contrast agents for MR imaging: preliminary studies in rats and humans. AJR Am J Roentgenol. 1987;148(6):1259–1263.
   PubMed Web of Science ®Google Scholar
• Mattrey RF, Hilpert PL, Levine D, et al. PFOB as a negative oral MR contrast agent identifies bowel clinical results. Invest Radiol. 1988;23(9):S3–S3.
   PubMed Web of Science ®Google Scholar
• Flaim SF. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Cells Blood Substit Immobil Biotechnol. 1994;22(4):1043–1054.
   PubMed Web of Science ®Google Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–951.
   PubMed Web of Science ®Google Scholar
• Riess JG. Oxygen carriers (“blood substitutes")-raison d'etre, chemistry, and some physiology”). Chem Rev. 2001;101(9):2797–2920.
   PubMed Web of Science ®Google Scholar
• André M, Nelson T, Mattrey R. Physical and acoustical properties of perfluorooctylbromide, an ultrasound contrast agent. Invest Radiol. 1990;25(9):983–987.
   PubMed Web of Science ®Google Scholar
• Astafyeva K, Somaglino L, Desgranges S, et al. Perfluorocarbon nanodroplets stabilized by fluorinated surfactants: characterization and potentiality as theranostic agents. J Mater Chem B. 2015;3(14):2892–2907.
   PubMed Web of Science ®Google Scholar
• Lorton O, Hyacinthe J-N, Desgranges S, et al. Molecular oxygen loading in candidate theranostic droplets stabilized with biocompatible fluorinated surfactants: Particle size effect and application to in situ19F MRI mapping of oxygen partial pressure. J Magn Reson. 2018;295:27–37.
   PubMed Web of Science ®Google Scholar
• Contino-Pepin C, Maurizis J, Pucci B. Amphiphilic oligomers: a new kind of macromolecular carrier of antimitotic drugs. Curr Med Chem Anticancer Agents. 2002;2(6):645–665.
   PubMedGoogle Scholar
• Hindman JC. Proton resonance shift of water in the gas and liquid states. The Journal of Chemical Physics. 1966;44(12):4582–4592.
   Web of Science ®Google Scholar
• Cornelis F, Grenier N, Moonen CT, et al. In vivo characterization of tissue thermal properties of the kidney during local hyperthermia induced by MR‐guided high‐intensity focused ultrasound. NMR Biomed. 2011;24(7):799–806.
   PubMed Web of Science ®Google Scholar
• Bera C, Devarakonda SB, Kumar V, et al. The mechanism of nanoparticle-mediated enhanced energy transfer during high-intensity focused ultrasound sonication. Phys Chem Chem Phys. 2017;19(29):19075–19082.
   PubMed Web of Science ®Google Scholar
• Shi WT, Gao S, Francois V, et al., editors. Investigation of effectiveness of microbubble stable cavitation in thrombolysis. IEEE International Ultrasonics Symposium; 2010.
   Google Scholar
• Melich R, Bussat P, Morici L, et al. Microfluidic preparation of various perfluorocarbon nanodroplets: Characterization and determination of acoustic droplet vaporization (ADV) threshold. Int J Pharm. 2020;587:119651.
   PubMed Web of Science ®Google Scholar
• Crake C, Meral FC, Burgess MT, et al. Combined passive acoustic mapping and magnetic resonance thermometry for monitoring phase-shift nanoemulsion enhanced focused ultrasound therapy. Phys Med Biol. 2017;62(15):6144–6163.
   PubMed Web of Science ®Google Scholar
• Jensen CR, Ritchie RW, Gyöngy M, et al. Spatiotemporal monitoring of high-intensity focused ultrasound therapy with passive acoustic mapping. Radiology. 2012;262(1):252–261.
   PubMed Web of Science ®Google Scholar
• Datta S, Coussios C-C, McAdory LE, et al. Correlation of cavitation with ultrasound enhancement of thrombolysis. Ultrasound Med Biol. 2006;32(8):1257–1267.
   PubMed Web of Science ®Google Scholar
• Hitchcock KE, Ivancevich NM, Haworth KJ, et al. Ultrasound-enhanced rt-PA thrombolysis in an ex vivo porcine carotid artery model. Ultrasound Med Biol. 2011;37(8):1240–1251.
   PubMed Web of Science ®Google Scholar
• Prokop AF, Soltani A, Roy RA. Cavitational mechanisms in ultrasound-accelerated fibrinolysis. Ultrasound Med Biol. 2007;33(6):924–933.
   PubMed Web of Science ®Google Scholar
• Sharma R, Sharma S. Physiology, blood volume. Treasure Island (FL): StatPearl Publishing; 2020.
   Google Scholar
• Astafyeva K. Physical and acoustical properties of fluorocarbon nanoparticles [doctoral dissertation]. Paris, France: Université Pierre et Marie Curie – Paris VI; 2014.
   Google Scholar
• Maurizis JC, Azim M, Rapp M, et al. Disposition in rat of a new fluorinated, biocompatible, non-ionic telomeric carrier. Xenobiotica. 1994;24(6):535–541.
   PubMed Web of Science ®Google Scholar
• Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Del Rev. 1995; 16(2-3):285–294.
   Web of Science ®Google Scholar